Abstract:Purpose Dexmedetomidine (Dexmed) is a highly selective alpha 2 adrenoceptor (α 2 -AR) agonist with excellent sedation and analgesic effects and is frequently used in breast cancer surgery. However, the exact impact of Dexmed on breast cancer prognosis is still unclear. The primary objective of this pilot study was to explore study feasibility (recruitment and dropout rates) for future large-scale randomized controlled trial (RCT) to test the hypothesis that intraoperative Dexmed reduced recurrence-free survival (RFS) and overall survival (OS) in patients after breast cancer surgery. Methods Interviews with patients were performed during the anesthetic preoperative visit for informed consent. Adult females scheduled for a mastectomy due to primary breast cancer were 1:1 randomised to saline (Group Control) or Dexmed (Group Dexmed) treatment groups. The primary outcomes were descriptions of study feasibility (recruitment and dropout rates). We also performed a preliminary analysis of RFS (time from surgery to the earliest date of recurrence/metastasis) and OS (time from surgery to the date of all-cause death) and collected data on percentages/numbers of circulating immune cells at pre- and 24 h post-operation. Results A total of 964 patients were screened; 40% (385/964) met the inclusion criteria, among which 39% (150/385) were enrolled and randomly assigned to either Group Control ( n = 75) or Group Dexmed ( n = 75). The median follow-up duration was 49 months (interquartile range (IQR): 34–58 months) for Group Control and 48 months (IQR: 33–60 months) for Group Dexmed. Five percent (5%, 8/150) patients were lost to follow-up and 1% (2/150) died. There was no significant difference in RFS and OS. The percentage/number of natural killer (NK), B and T-cell subsets and the CD4 + /CD8 + ratio were similar between groups at 24 h post-operation. Conclusion The pilot study was feasible to deliver. In a future definitive trial, the lower recruitment rate may be improved by increasing the number of anesthesiologists involved in the study. The study about the effects of Dexmed on long-term prognoses of breast cancer patients that is planned to follow this pilot study is a large-scaled randomized control study with the aim of providing evidence-based guidelines for rational use of Dexmed in patients undergoing breast cancer surgery. Trial registration Registered at ClinicalTrials.gov on October 20, 2016 (ID: NCT03109990). Graphical Abstract

Effect of dexmedetomidine on proliferation, migration and invasion of human gastric cancer SGC-7901 cells

Study on effect of cox-2 inhibitor on proliferation and invasion of human gastric cancer cells

Apoptosis of SGC7901 Gastric Cancer Cell Induced by Cyanidin-3-glucoside

Influence of Up-Regulation of Notch Ligand DLL4 on Biological Behaviors of Human Gastric Cancer Cells.

Dexmedetomidine protects against oxygen-glucose deprivation-induced injury through the I2 imidazoline receptor-PI3K/AKT pathway in rat C6 glioma cells.

Effects of Dexmedetomidine on Proliferation, Invasion, Migration and Angiogenesis of Hypoxia-Induced HepG2 Liver Cancer Cells

Effect of Diterpenoid C from Radix Curcumae on Proliferation of Human Gastric Cancer Cells SGC-7901

Effects of dexmedetomidine on A549 non-small cell lung cancer growth in a clinically relevant surgical xenograft model

Effects of Serum from Breast Cancer Surgery Patients Receiving Perioperative Dexmedetomidine on Breast Cancer Cell Malignancy: A Prospective Randomized Controlled Trial

In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway.

Effects of dexmedetomidine on the glycometabolism rate-limiting enzymes in erythrocytes and the plasma levels of glucose and malondialdehyde in patients undergoing radicalgastrectomy for cancer

Dextran Sulfate Effects EMT of Human Gastric Cancer Cells by Reducing HIF-1α/ TGF-β

Dextran sulfate inhibits proliferation and metastasis of human gastric cancer cells via miR-34c-5p

Effect of GSK-3β on Proliferation and Invasion of Endometrioid Adenocarcinoma

Effect of DDX20 Gene on the Migration of Gastric Carcinoma Cell

Dexmedetomidine inhibits the migration, invasion, and glycolysis of glioblastoma cells by lactylation of c-myc

The Effects of Dexmedetomidine on Postoperative Tumor Recurrence and Patient Survival after Breast Cancer Surgery: a Feasibility Study

Dexamethasone inhibits the proliferation of tumor cells

Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials

Effects of Dexmedetomidine and Propofol on Postoperative Analgesia and the Cellular Immune Function of Patients Undergoing Radical Gastrectomy for Gastric Cancer

Dexmedetomidine promotes ferroptotic cell death in gastric cancer via hsa_circ_0008035/miR-302a/E2F7 axis